Diagnostic Technologies Ltd., Yoqneam, Israel.
Placenta. 2011 Feb;32 Suppl:S30-6. doi: 10.1016/j.placenta.2010.09.006.
To compare the distribution of placental protein 13 (PP13) in fetal and maternal blood and amnionic fluid and to correlate it with PP13 protein and mRNA in the placenta.
Umbilical arterial serum, amnionic fluid, maternal venous serum and placental tissues were collected from normal outcome pregnancies (N = 63) (GA>37), early onset preeclampsia (PE) (N = 12, GA: 26-33), and HELLP syndrome (N = 5, GA: 27-29). Because PE and HELLP cases delivered preterm, cases of preterm delivery (PTD) (N = 6, GA: 31-36) served as additional control. PP13 was determined by ELISA, Western blot, and immunohistochemistry. PP13 mRNA was measured by PCR (RT-PCR). Continuous parameters were compared by t-test, P < 0.05 was considered significant.
In women with normal pregnancy outcome significantly higher PP13 levels were found in maternal serum compared to amnionic fluid and negligible amount was found in fetal serum. A similar pattern was identified in cases of PTD with concentrations similar to term control. In PE and HELLP cases PP13 levels in amnionic fluid level were more than twice compared to maternal serum (P < 0.001). Umbilical cord level was negligible in PE but high in HELLP corresponding to the much higher level of PP13 in this patient group compared to all others. In the placenta PP13 level in term controls was higher compared to PTD. In PE and HELLP (similar early delivery time as PTD) the level was significantly higher (P < 0.01) compared to PTD or term controls. PP13 mRNA levels in term control and PTD were similar while PP13 mRNA levels in PE and HELLP placentas were significantly lower compared to term controls or PTD or the two combined. Syncytiotrophoblast labeling appeared stronger in PE and HELLP compared to term controls and PTD.
In all cases but HELLP, PP13 in fetal blood is very low indicating that routing of PP13 to fetal blood is limited and that the fetus is unlikely to generate PP13. PP13 mRNA is lower in the third trimester at the time of disease while protein level accumulates and become higher creating an unparallel change in the level of the mRNA and the corresponding protein.
比较胎盘蛋白 13（PP13）在胎儿和产妇血液及羊水中的分布，并将其与胎盘内的 PP13 蛋白和 mRNA 进行相关性分析。
收集来自正常足月分娩（GA>37）（N=63）、早发型子痫前期（PE）（N=12，GA：26-33）和 HELLP 综合征（N=5，GA：27-29）的产妇脐动脉血清、羊水、产妇静脉血清和胎盘组织。由于 PE 和 HELLP 病例均为早产分娩，故另设早产（PTD）组（N=6，GA：31-36）作为对照。采用 ELISA、Western blot 和免疫组化法检测 PP13，PCR（RT-PCR）检测 PP13 mRNA。采用 t 检验比较连续参数，P<0.05 为差异有统计学意义。
在正常妊娠结局的女性中，母体血清中的 PP13 水平明显高于羊水，而胎儿血清中的 PP13 水平可忽略不计。PTD 患者的检测结果也呈现类似的模式，其浓度与足月对照组相似。在 PE 和 HELLP 患者中，羊水与母体血清的 PP13 比值为 2 倍以上（P<0.001）。PE 患者的脐静脉水平可忽略不计，但在 HELLP 患者中水平较高，这与该患者组的 PP13 水平明显高于其他所有组相一致。在胎盘组织中，足月对照组的 PP13 水平高于 PTD。在 PE 和 HELLP（与 PTD 相似的早期分娩时间）中，PP13 水平明显高于 PTD 或足月对照组（P<0.01）。足月对照组和 PTD 的 PP13 mRNA 水平相似，而 PE 和 HELLP 胎盘组织中的 PP13 mRNA 水平明显低于足月对照组或 PTD 或两者的总和。与足月对照组和 PTD 相比，PE 和 HELLP 的合体滋养层标记明显更强。
除 HELLP 外，胎儿血液中的 PP13 水平非常低，这表明 PP13 向胎儿血液的转运是有限的，胎儿不太可能产生 PP13。在疾病发生的孕晚期，PP13 mRNA 水平下降，而蛋白水平升高，导致 mRNA 及其相应蛋白的水平呈非平行变化。
